Primary biliary cirrhosis in adults

Njideka Momah, Keith Lindor

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Primary biliary cirrhosis (PBC) is a chronic, autoimmune, cholestatic liver disease. It is characterized by slow destruction of small intrahepatic bile ducts, impaired biliary secretion and stasis of toxic endogenous bile acids within the liver with progression to liver fibrosis and cirrhosis. It has an increasing prevalence worldwide. It occurs more commonly in women than men at a ratio of 10:1. In most cases, diagnosis relies on a positive antimitochondrial antibody in the context of chronic cholestasis, without the need for a liver biopsy. Ursodeoxycholic acid improves survival even in patients with advanced liver disease. Certain findings such as fatigue, anti-nuclear antibodies, anti-centromere antibodies and the GP210 antinuclear antibody predict a poor outcome. Up to 40% of patients do not respond satisfactorily to ursodeoxycholic acid therapy and should be considered for adjunctive therapies. Several adjunctive and newer therapies are being tested and some appear promising. We provide a review of PBC with a focus on advances in therapies that may impact the management of PBC in the near future.

Original languageEnglish (US)
Pages (from-to)427-433
Number of pages7
JournalExpert Review of Gastroenterology and Hepatology
Volume8
Issue number4
DOIs
StatePublished - 2014

Fingerprint

Biliary Liver Cirrhosis
Ursodeoxycholic Acid
Cholestasis
Liver Cirrhosis
Liver Diseases
Anti-Idiotypic Antibodies
Intrahepatic Bile Ducts
Centromere
Poisons
Liver
Antinuclear Antibodies
Therapeutics
Bile Acids and Salts
Fatigue
Biopsy
Survival
Antibodies

Keywords

  • adjunctive therapy
  • farnesoid X receptor agonist
  • obeticholic acid
  • primary biliary disease
  • ursodeoxycholic acid

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology
  • Medicine(all)

Cite this

Primary biliary cirrhosis in adults. / Momah, Njideka; Lindor, Keith.

In: Expert Review of Gastroenterology and Hepatology, Vol. 8, No. 4, 2014, p. 427-433.

Research output: Contribution to journalArticle

@article{d7c9291b6db64d7a86fa5de4270e9fbc,
title = "Primary biliary cirrhosis in adults",
abstract = "Primary biliary cirrhosis (PBC) is a chronic, autoimmune, cholestatic liver disease. It is characterized by slow destruction of small intrahepatic bile ducts, impaired biliary secretion and stasis of toxic endogenous bile acids within the liver with progression to liver fibrosis and cirrhosis. It has an increasing prevalence worldwide. It occurs more commonly in women than men at a ratio of 10:1. In most cases, diagnosis relies on a positive antimitochondrial antibody in the context of chronic cholestasis, without the need for a liver biopsy. Ursodeoxycholic acid improves survival even in patients with advanced liver disease. Certain findings such as fatigue, anti-nuclear antibodies, anti-centromere antibodies and the GP210 antinuclear antibody predict a poor outcome. Up to 40{\%} of patients do not respond satisfactorily to ursodeoxycholic acid therapy and should be considered for adjunctive therapies. Several adjunctive and newer therapies are being tested and some appear promising. We provide a review of PBC with a focus on advances in therapies that may impact the management of PBC in the near future.",
keywords = "adjunctive therapy, farnesoid X receptor agonist, obeticholic acid, primary biliary disease, ursodeoxycholic acid",
author = "Njideka Momah and Keith Lindor",
year = "2014",
doi = "10.1586/17474124.2014.888950",
language = "English (US)",
volume = "8",
pages = "427--433",
journal = "Expert Review of Gastroenterology and Hepatology",
issn = "1747-4124",
publisher = "Expert Reviews Ltd.",
number = "4",

}

TY - JOUR

T1 - Primary biliary cirrhosis in adults

AU - Momah, Njideka

AU - Lindor, Keith

PY - 2014

Y1 - 2014

N2 - Primary biliary cirrhosis (PBC) is a chronic, autoimmune, cholestatic liver disease. It is characterized by slow destruction of small intrahepatic bile ducts, impaired biliary secretion and stasis of toxic endogenous bile acids within the liver with progression to liver fibrosis and cirrhosis. It has an increasing prevalence worldwide. It occurs more commonly in women than men at a ratio of 10:1. In most cases, diagnosis relies on a positive antimitochondrial antibody in the context of chronic cholestasis, without the need for a liver biopsy. Ursodeoxycholic acid improves survival even in patients with advanced liver disease. Certain findings such as fatigue, anti-nuclear antibodies, anti-centromere antibodies and the GP210 antinuclear antibody predict a poor outcome. Up to 40% of patients do not respond satisfactorily to ursodeoxycholic acid therapy and should be considered for adjunctive therapies. Several adjunctive and newer therapies are being tested and some appear promising. We provide a review of PBC with a focus on advances in therapies that may impact the management of PBC in the near future.

AB - Primary biliary cirrhosis (PBC) is a chronic, autoimmune, cholestatic liver disease. It is characterized by slow destruction of small intrahepatic bile ducts, impaired biliary secretion and stasis of toxic endogenous bile acids within the liver with progression to liver fibrosis and cirrhosis. It has an increasing prevalence worldwide. It occurs more commonly in women than men at a ratio of 10:1. In most cases, diagnosis relies on a positive antimitochondrial antibody in the context of chronic cholestasis, without the need for a liver biopsy. Ursodeoxycholic acid improves survival even in patients with advanced liver disease. Certain findings such as fatigue, anti-nuclear antibodies, anti-centromere antibodies and the GP210 antinuclear antibody predict a poor outcome. Up to 40% of patients do not respond satisfactorily to ursodeoxycholic acid therapy and should be considered for adjunctive therapies. Several adjunctive and newer therapies are being tested and some appear promising. We provide a review of PBC with a focus on advances in therapies that may impact the management of PBC in the near future.

KW - adjunctive therapy

KW - farnesoid X receptor agonist

KW - obeticholic acid

KW - primary biliary disease

KW - ursodeoxycholic acid

UR - http://www.scopus.com/inward/record.url?scp=84899024760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899024760&partnerID=8YFLogxK

U2 - 10.1586/17474124.2014.888950

DO - 10.1586/17474124.2014.888950

M3 - Article

C2 - 24580040

AN - SCOPUS:84899024760

VL - 8

SP - 427

EP - 433

JO - Expert Review of Gastroenterology and Hepatology

JF - Expert Review of Gastroenterology and Hepatology

SN - 1747-4124

IS - 4

ER -